Received Aug 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | OT |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | OT |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | — | OT |
patient has tested positive for HPV; irst dose of GARDASIL 9 in 2019, their second in 2024 and their third 6 months later; This spontaneous report was received from a Physician and refers to a female patient of unknown age. The patient's medical history, concurrent conditions and concomitant therapies were not reported. In 2019, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), then in 2024 she received the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), and 6 months later, she received the third dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9) (Inappropriate schedule of vaccine administration). No lot # and expiration date were not reported for any dose, all administered by Unknown route for human papilloma virus (HPV). On an unknown date, HPV test showed Positive. Patient has had a colposcopy; however results were unknown at time of report. At the reporting time, the outcome of the event was unknown. The causal relationship between the event of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9) was not reported. Batch/Lot number is being requested and will be submitted if received.
Test Name: HPV Test; Test Result: Positive